Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Conditions
Interventions
Samidorphan (Low Dose)
Samidorphan (Medium Dose)
+3 more
Locations
61
United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Anaheim, California, United States
Alkermes Investigational Site
Costa Mesa, California, United States
Alkermes Investigational Site
Culver City, California, United States
Alkermes Investigational Site
Escondido, California, United States
Alkermes Investigational Site
Garden Grove, California, United States
Start Date
June 1, 2013
Primary Completion Date
December 1, 2014
Completion Date
March 1, 2015
Last Updated
October 6, 2021
NCT06894212
NCT04226898
NCT05240976
NCT06745479
NCT07455929
NCT05304767
Lead Sponsor
Alkermes, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions